Unknown

Dataset Information

0

Transcriptional profiling of matched patient biopsies clarifies molecular determinants of enzalutamide-induced lineage plasticity.


ABSTRACT: The androgen receptor (AR) signaling inhibitor enzalutamide (enza) is one of the principal treatments for metastatic castration-resistant prostate cancer (CRPC). Several emergent enza clinical resistance mechanisms have been described, including lineage plasticity in which the tumors manifest reduced dependency on the AR. To improve our understanding of enza resistance, herein we analyze the transcriptomes of matched biopsies from men with metastatic CRPC obtained prior to treatment and at progression (n = 21). RNA-sequencing analysis demonstrates that enza does not induce marked, sustained changes in the tumor transcriptome in most patients. However, three patients' progression biopsies show evidence of lineage plasticity. The transcription factor E2F1 and pathways linked to tumor stemness are highly activated in baseline biopsies from patients whose tumors undergo lineage plasticity. We find a gene signature enriched in these baseline biopsies that is strongly associated with poor survival in independent patient cohorts and with risk of castration-induced lineage plasticity in patient-derived xenograft models, suggesting that tumors harboring this gene expression program may be at particular risk for resistance mediated by lineage plasticity and poor outcomes.

SUBMITTER: Westbrook TC 

PROVIDER: S-EPMC9477876 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Transcriptional profiling of matched patient biopsies clarifies molecular determinants of enzalutamide-induced lineage plasticity.

Westbrook Thomas C TC   Guan Xiangnan X   Rodansky Eva E   Flores Diana D   Liu Chia Jen CJ   Udager Aaron M AM   Patel Radhika A RA   Haffner Michael C MC   Hu Ya-Mei YM   Sun Duanchen D   Beer Tomasz M TM   Foye Adam A   Aggarwal Rahul R   Quigley David A DA   Youngren Jack F JF   Ryan Charles J CJ   Gleave Martin M   Wang Yuzhuo Y   Huang Jiaoti J   Coleman Ilsa I   Morrissey Colm C   Nelson Peter S PS   Evans Christopher P CP   Lara Primo P   Reiter Robert E RE   Witte Owen O   Rettig Matthew M   Wong Christopher K CK   Weinstein Alana S AS   Uzunangelov Vlado V   Stuart Josh M JM   Thomas George V GV   Feng Felix Y FY   Small Eric J EJ   Yates Joel A JA   Xia Zheng Z   Alumkal Joshi J JJ  

Nature communications 20220915 1


The androgen receptor (AR) signaling inhibitor enzalutamide (enza) is one of the principal treatments for metastatic castration-resistant prostate cancer (CRPC). Several emergent enza clinical resistance mechanisms have been described, including lineage plasticity in which the tumors manifest reduced dependency on the AR. To improve our understanding of enza resistance, herein we analyze the transcriptomes of matched biopsies from men with metastatic CRPC obtained prior to treatment and at progr  ...[more]

Similar Datasets

| S-EPMC5976814 | biostudies-literature
| S-EPMC8800106 | biostudies-literature
| S-EPMC4687867 | biostudies-literature
| S-EPMC10527883 | biostudies-literature
| S-EPMC10135924 | biostudies-literature
| S-EPMC5837116 | biostudies-literature
| S-EPMC7275746 | biostudies-literature
| S-EPMC8546046 | biostudies-literature
| S-SCDT-10_1038-S44318-025-00424-1 | biostudies-other
| S-EPMC4514973 | biostudies-literature